Syncona makes additional push for gene therapy dominance

Less than a week after setting up two new companies with a $35 million investment, life sciences trust Syncona (LSE:SYBC)  is making more waves in gene therapy by contributing £85 million ($112 million) to Freeline Therapeutics' Series B funding campaign.

Freeline is a clinical-stage gene therapy company focused on indications of chronic, systemic diseases particularly in the liver. Co-founded by Syncona and Amit Nathwani from University College London (UCL) in 2015, it will use this funding to push its hemophilia B vector to trial.

"We believe in backing our companies strongly over the long term"